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Background: Specific germline mutations in the hereditary breast-ovarian cancer susceptibility (HBC/HBOC) genes,
BRCA1, BRCA2 and PALB2, have been shown to recur in French Canadians of Quebec, Canada, and this has been
attributed to common ancestors. Germline TP53 mutation carriers are known to segregate in Li-Fraumeni syndrome
families, which feature young age of onset breast cancer. We have reported rare TP53 mutation carriers in French
Canadian HBC families, though none recurred possibly due to the limited number of cancer families investigated.
Here we describe TP53 germline mutations found in French Canadian cancer families provided from hereditary
cancer clinics; investigate 37 new BRCA1 and BRCA2 mutation-negative HBC/HBOC families for the TP53 mutations;
and assess the frequency of TP53 mutations in a 1235 French Canadian breast cancer cases not selected for family
history of cancer.
Methods: TP53 mutation-positive pedigrees from French Canadian cancer families were provided from local hereditary
cancer clinics. Bidirectional Sanger sequencing of all protein encoding exons of TP53 was performed using peripheral
blood lymphocyte DNA from breast/ovarian cancer probands from 37 HBC/HBOC families of French Canadian descent.
Targeted bidirectional Sanger sequencing assay of regions containing the identified TP53 mutations was performed on
1235 French Canadian breast cancer cases not selected for family history cancer.
Results: Five new TP53 mutations were identified in six pedigrees from hereditary cancer clinics. No deleterious
mutations were identified in cancer probands from 37 HBC/HBOC families. A targeted mutation screen of the 1235
breast cancer cases identified a c.844C>T [p.Arg282Trp] mutation carrier. This mutation was also found among the six
mutation-positive cancer families provided by the local hereditary cancer clinics. The targeted screen also uncovered a
new TP53 mutation, c.685T>C [p.Cys229Arg] that was found in two breast cancer cases. All TP53 mutation carriers were
among the 656 women with breast cancer diagnosed less than 50 years of age.
Conclusions: In all six new TP53 mutations were identified in French Canadians, where two each occurred in
independently ascertained cases/families. Although all newly identified breast cancer mutation carriers reported a
family history of cancer, none were consistent with features of Li-Fraumeni syndrome families.
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Germline TP53 mutations have been reported in rare in-
stances of hereditary breast cancer (HBC) and hereditary
breast and ovarian cancer (HBOC) syndrome families
found negative for mutations in the BRCA1 and BRCA2
breast and ovarian cancer susceptibility genes. TP53,
BRCA1 and BRCA2 mutation carriers share in common
a significant risk for premenopausal breast cancer with
estimated lifetime risks of 80-90%, 60-85% and 40-85%,
respectively [1]. The rarity of TP53 mutation carrier
HBC/HBOC families reflects the estimated 0.025% fre-
quency of mutation carriers in the population [1]. This is in
stark contrast with the estimated 0.1% frequency of
BRCA1/BRCA2 mutation carriers in the population and is
consistent with the observation that a significant number of
HBC/HBOC families (>40%) harbor mutations these genes
[1]. Although other breast cancer risk alleles of moderate
penetrance have recently been identified, only BRCA1 and
BRCA2 are routinely evaluated in genetic counseling set-
tings in order to identify carriers for purposes of assessing
cancer risk and offering management strategies for cancer
detection and prevention [2]. Rarely are TP53 mutations in-
vestigated in HBC/HBOC families due the estimated low
frequency (<1%) of carriers in breast cancer cases and the
observation that 70% of carriers are found in Li-Fraumeni
Syndrome (LFS) families [1]. In addition to premenopausal
breast cancer, LFS families feature a wide spectrum of can-
cer types with an excess of young age of onset soft tissue
and bone sarcomas, brain tumors and adrenocortical car-
cinomas [3]. However, breast cancer cases in the context of
LFS accounts for less than 0.1% of all such cancer cases [1].
Thus TP53 mutation-positive LFS families may not identify
all possible mutation carrier breast cancer cases.
Identifying TP53 mutation carriers is important as evi-
dence suggests that mutation carrier LFS patients have an
abnormal response to low dose radiation and should avoid
radiation therapy whenever possible in order to limit the
risk of secondary radiation-induced malignancies [4]. This
finding raises the question of mutation screening practices.
Mutation screening is recommended in the context of LFS
and similar syndromes (LFS-like syndrome (LFL)) with
overlapping clinical features of core cancers but not neces-
sarily features of HBC/HBOC [1,3,5]. For example, the
American Cancer Society recommends magnetic resonance
imaging (MRI) for breast cancer screening in mutation car-
rier women in LFS families [6].
Routine screening for germline TP53 mutations in
breast cancer cases has not been advocated due to the
low estimated frequency of carriers. The frequency of
carriers in the population is currently unknown. Various
estimates have been made based on the genetic analyses
of LFS families, breast cancer families, and often from
age-selected cases of breast cancer [1,5]. In a recent study
of 28 women with diagnoses of breast cancer before age30 years, TP53 mutation carriers were found in 33.3% of
the cases where 7.7% did not meet criteria for LSF [7]. In
the United Kingdom, it is estimated that 6% of women with
breast cancer under age 31 years carry TP53 mutations,
and based on this evidence, a prevalence of 1/10,000 to
1/25,000 live births harboring pathogenic mutations
was estimated [8]. The significance of mutation carriers
the young age of onset breast cancer has resulted in
recommendations from the National Comprehensive
Cancer Network® for clinical practice of genetic/familial
high risk cases of breast and ovarian cancers to test
(concurrent with or following genetic testing of BRCA1
and BRCA2) women with breast cancer diagnoses less
than age 35 years of age [9].
We have reported germline TP53 mutations in 3.8% of
52 HBC/HBOC families of French Canadian descent
found negative for BRCA1 and BRCA2 mutations [10].
Our initial study was prompted by the observation of a
TP53 mutation-positive HBC French Canadian family
that also exhibited LFS features [10]. However, none of
the two subsequently identified mutation-positive fam-
ilies in our study, exhibited features of the core cancers
found in LFS families [10]. The carrier frequency of
TP53 mutations in the French Canadian population of
Quebec is unknown. A targeted analysis of c.638G>A
[p.Arg213Gln] and c.869G>A [p.Arg290His], mutations
initially found in a TP53 mutation screen of HBC fam-
ilies, did not identify any additional carriers among the
381 French Canadian women with breast cancer before
age 50 years that were not selected for a family history
of cancer [10]. The French Canadian population is known
for exhibiting strong founder effects as indicated by the re-
currence of specific BRCA1 and BRCA2 germline muta-
tions in HBC/HBOC families [11,12]. Since our report of
TP53 mutations, a specific mutation in a moderately pene-
trant breast cancer susceptibility gene, PALB2 (c.2323C>T
[p.Gln775Ter]), has been found to recur in French Canad-
ian HBC families and breast cancer cases [13,14]. Although
there is currently no evidence of recurring TP53 mutations
in this founder population, our report remains the only
study that has focused on TP53 mutation analysis of French
Canadian women with breast cancer [10].
To further characterized the spectrum of TP53 germ-
line mutations in French Canadians, we describe the
mutations found in hereditary cancer clinics, investigate
breast/ovarian cancer probands from 37 new HBC/HBOC
families found negative for BRCA1 and BRCA2 germline
mutations, and report on the frequency of mutations found
in a targeted screen of 1235 French Canadian breast cancer
cases for TP53 mutations found in hereditary cancer fam-
ilies. Five new TP53 mutations in French Canadian cancer
families were identified among the six pedigrees provided
by local hereditary cancer clinics. No new TP53 mutations
were identified in the 37 probands from new HBC/HBOC
Arcand et al. BMC Medical Genetics  (2015) 16:24 Page 3 of 11families. However, a screen of genomic regions found mu-
tated in French Canadian cancer families identified a breast
cancer case harboring the c.844C>T [p.Arg282Trp] muta-
tion. This mutation was also identified among one of the
six families (LFL) provided by the hereditary cancer clinics.
Two breast cancer cases each carrying a c.685T>C
[p.Cys229Arg] mutation were also found. All mutation car-
riers from screening the breast cancer cases were among
the 656 women diagnosed less than 50 years of age. The re-
sults from this study will inform the development of
mutation-screening policies for women with breast cancer
in the Quebec population.
Methods
TP53 mutation carrier pedigrees from hereditary cancer
clinics
Pedigrees from TP53 mutation-positive carriers of
French Canadian descent from the Quebec population
were requested from hereditary cancer clinics. From this
request, six TP53 mutation carrier pedigrees (F171,
F187, F1580, F1581, F1582 and F1583) were provided to
the study by the hereditary cancer clinics affiliated with
the McGill University Health Centre (MUHC), Jewish
General Hospital and Centre hospitalier de l'Université
de Montréal (CHUM) (Figures 1,2,3,4 and 5). All index
cases carrying a TP53 mutation in the pedigrees self
reported French Canadian (Quebec) ancestry. The ped-
igrees were provided along with the TP53 mutation re-
sults as indicated on the pedigrees, and not all cancer
phenotypes indicated on the pedigrees (to our know-
ledge) were confirmed. The adrenocortical carcinomas
(ACC) cases in pedigrees F171 (Figure 1) and F187
(Figure 2) were described in an earlier study of the role
of germline TP53 mutations in childhood ACC but theFigure 1 Pedigree of family F171 harboring the TP53 mutation c.703A>G [
adrenocortical carcinoma (ACC) and ovarian cancer (Ov). Age in years or w
are shown.pedigrees had not been previously reported [15]. The
proband in Family F1581 had been tested due to prior
knowledge of a TP53 mutation carrier in a family with
childhood ACC (Figure 2). In the context of this study,
this individual was found related to members of pedigree
F187 (as described further in the Results section). The
remaining three families (F1580, F1582, and F1583) that
were provided to the study were tested for TP53 because
they each had at least one LFS spectrum cancer.
Table 1 includes information for all TP53 mutation
positive pedigrees that were provided by the hereditary
cancer clinics as described above. Table 1 also includes
information for three other pedigrees (F875, F1039 and
F1444) that have been described previously in the con-
text of the TP53 mutation screening study of HBC fam-
ilies from our group [10]. The recruitment criteria for
these pedigrees have been described (see Study Subjects
for familial cases below) [10]. As F875, F1039 and F1444
pedigrees were published previously [10] they are not
reproduced in this report.
Study subjects
One group of study subjects was comprised of cancer-
affected index cases from 37 independently ascertained
HBC/HBOC cancer families. The index cases were re-
cruited through the hereditary cancer clinics affiliated with
the MUHC and CHUM as part of research studies of
BRCA1/BRCA2 mutations in families of French Canadian
(Quebec) origin as described previously [10,16]. There were
25 HBC and 12 HBOC families defined as follows: in
addition to the index case affected with breast cancer at less
than 66 years of age (n = 33) or ovarian cancer case at any
age (n = 4), the families had at least two other confirmed
cases of invasive breast (less than 66 years of age) and/orp.Asn235Asp]. Cancer type or site followed by age of diagnosis for
eeks (wks) or age at death (d.) if known at time of ascertainment
Figure 2 Pedigrees of families F187 and F1581 harboring the TP53 mutation c.655C>T [p.Pro219Ser]. Cancer type or site followed by age of
diagnosis for adrenocortical carcinoma (ACC), breast cancer (Br), prostate cancer (Pro) and primary site unknown (PSU). Age in years or age at
death (d.) if known at time of ascertainment are shown.
Figure 3 Pedigree of family F1580 harboring the TP53 mutation c.742C>T [p.Arg248Trp]. Cancer site followed by age of diagnosis for cancers of
the brain (Bt), colon (Co), kidney (Kd), lung (Lu), pancreas (Pan), prostate (Pro), skin (Sk), and throat (Thr). Age in years or age at death (d.) if known
at time of ascertainment are shown.
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Figure 4 Pedigree of family F1582 harboring the TP53 mutation c.730G>A [p.Gly244Ser]. Cancer type or site followed by age of diagnosis for
breast cancer (Br), brain tumor (Bt), colon cancer (Co), ductal carcinoma in situ (DCIS), lung cancer (Lu), lung metastasis (Lu Mets), ovarian cancer
(Ov), prostate cancer (Pro), sarcoma (Sar), skin cancer (Sk), and throat cancer (Thr). Age in years or age at death (d.) if known at time of
ascertainment are shown.
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index case from each family had been evaluated for BRCA1
and BRCA2 mutations by commercial DNA sequencing
(Myriad Genetics, Myriad Genetics Laboratories, Salt Lake
City, UT, USA) and was found negative or found to harbor
a variant of unknown clinical significance [12,16]. Genomic
DNA was provided by the Banque de tissus et de données
of the Réseau de recherche sur le cancer of the Fonds de
recherche du Québec - Santé.
Another group of study subjects was comprised of 1235
French Canadian women with invasive breast cancer thatFigure 5 Pedigree of family F1583 harboring the TP53 mutation c.844C>T
liposarcoma (Lip), breast cancer (Br), metastatic lesions (Mets), pancreas can
known at time of ascertainment are shown.were not selected based on a family history of cancer. In
this group were 656 women that were diagnosed before
50 years of age. They were recruited from a breast cancer
out patient clinic affiliated with the CHUM and family his-
tory of cancer was collected as described previously [14,17].
Among these 1235 patients, there were 62 known carriers
of BRCA1, BRCA2, PALB2 or CHEK2 mutations [14,17].
Informed consent was obtained from all study subjects
and the study was performed in accordance with the
guidelines established by the respective institutional eth-
ical review boards.[p.Arg282Trp]. Cancer type or site followed by age of diagnosis for
cer (Pan), and prostate cancer (Pro). Age in years or age at death (d.) if
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c.638G>A p.Arg213Gln 6 BiBr38 F1039 yes Related to
F1444
A [8]
c.638G>A p.Arg213Gln 6 Br41 F1444 yes Related to
F1039
A [8]
c.655C>T p.Pro219Ser 6 ACC5 F187 yes Related to
F1581
B [13]
c.655C>T p.Pro219Ser 6 ACC1 F1581 yes Related to
F187
B This study
c.685T>C p.Cys229Arg 7 Br35;Br38 F1602 yes C This study
c.685T>C p.Cys229Arg 7 Br46 F1603 yes C This study
c.703A>G p.Asn235Asp 7 ACC2 F171 yes B [13]
c.730G>A p.Gly244Ser 7 Br29 F1582 yes B This study
c.742C>T p.Arg248Trp 7 Bt45 F1580 no B This study
c.844C>T p.Arg282Trp 8 Lip21 F1583 yes B This study
c.844C>T p.Arg282Trp 8 Br30;Br38 F1604 no C This study
c.869G>A p.Arg290His 8 Br44 F875 yes A [8]
Source of index cases from HBC families reported in a previous study of TP53 mutation (A) [8], new cancer families from hereditary cancer clinics (B) or from
breast cancer cases not selected for family history of cancer [(C); Index cases diagnosed with adrenocortical carcinoma (ACC), bilateral breast cancer (BiBr), breast
cancer (Br), brain tumor (Bt), or liposarcoma (Lip).
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A total of 37 probands from HBC/HBOC families were
investigated for TP53 germline mutations. The mutation
analysis of the index cases from 36 HBC/HBOC cancer
families was designed to detect variants in the protein
coding exons 2 to 11, and adjacent splice sites of TP53 as
described previously [18]. Briefly, PCR-based assays were
followed by bidirectional sequencing using the 3730XL
DNA Analyzer system (Life Technologies Inc., Burlington,
Canada) at the McGill University and Genome Quebec
Innovation Center (http://gqinnovationcenter.com). Com-
mercial sequencing was performed for an index case from
one of the HBOC families.
A targeted TP53 mutation analysis was performed for the
1235 breast cancer cases not selected for family history of
cancer. This analysis was designed to detect the mutations
that were found in French Canadian cancer families that
were provided from the hereditary cancer clinics (see
Table 1). As described above, mutation detection was based
on bidirectional Sanger sequencing of PCR products de-
rived from the amplification of exons 5 to 9.
Sequence chromatograms were compared with the NCBI
reference sequence (RefSeq) reported in GenBank: NM_
000546.4 and the genomic structures available from the
February 2009 GRCh37/hg19 assembly of the human refer-
ence genome. Sequence variants were compared with allele
frequencies reported in the Single Nucleotide Polymorph-
ism (SNP) Database (www.ncbi.nlm.nih.gov/SNP), NHLBI
Exome Sequencing Project (ESP): Exome Variant Server
(EVS) Database (http://evs.gs.washington.edu/EVS/), andinformation available in the International Agency for
Research on Cancer (IARC) TP53 Database version R17
November 2013 [19].
Results
Case review identifies new TP53 mutations in French
Canadian cancer families
In a genetic analysis of TP53 we initially reported three
mutation carrier HBC families of French Canadian des-
cent (F875, F1039 and F1444), where F1039 and F1444
harbored the same c.638G>A [p.Arg213Gln] mutation
and were found to be closely related following a case re-
view (Table 1) [10]. To further characterize the spectrum
of TP53 mutations in the French Canadian population
of Quebec, we requested mutation positive pedigrees
from hereditary cancer clinics based in Montreal, Que-
bec. Six TP53 mutation positive pedigrees (F171, F187,
F1580, F1581, F1582 and F1583) where provided to the
study along with carrier status and familial cancer pheno-
types (Figures 1,2,3,4 and 5). None of these pedigrees carry
the same mutations found in our previously reported HBC
families (Table 1). All mutations are missense and predicted
to affect the DNA binding domain of p53 based on the
IARC TP53 Database.
Three of pedigrees provided by the hereditary cancer
clinics had at least one pediatric ACC case (F171, F187 and
F1581) (Figures 1 and 2). As mentioned above (see
Methods), the ACC cases in families F171 and F187 were
tested for TP53 in the context of a study evaluating germ-
line TP53 mutation in this disease [15]. Interestingly,
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c.655C>T [p.Pro219Ser] (Figure 2). A review of the pedi-
grees and case histories suggested that these families are re-
lated through the ACC case diagnosed at five years of age.
The mutation was originally identified in this ACC case
and reported in a 1994 study, along with another ACC case
described in the unrelated family F171 (Figure 1), which
harbored a different mutation (c.703A>G [p.Asn235Asp]) )
(Table 1) [15]. The pedigrees shown depict a cancer family
history reported at the time the study was conducted. Not-
able is that each of these families reported a second-degree
relative with breast or ovarian cancer. Additional cancer
cases have since been reported for the ACC case linked to
family F187 (Figure 2). Family F1581 (Figure 2) is notable
for the further development of other ACC and breast can-
cer cases since it was initially presented (as F187).
The remaining families that were provided from the her-
editary cancer clinics (F1580, F1582 and F1583 (Figures 3,4
and 5)) had cancer cases consistent with LFS syndrome,
such as pediatric or young age of onset brain tumors and
sarcomas, and each family harbored a unique TP53 muta-
tion (Table 1). Although the confirmation of cancer cases
was not provided to the study, we were informed that the
presence of LFS spectrum cancer rationalized genetic test-
ing of TP53 in the hereditary cancer clinics.
Five of the six families, the exception being F1580
(Figure 3) provided by the hereditary cancer clinics, each



















c.1-140G>A intron 1 rs8079544 35 1
c.74+38C>G intron 2 rs1642785 3 12
c.96+41_96+56del16 intron 3 rs17878362 24 11
c.97-29C>A intron 3 rs17883323 35 1
c.108G>A p.Pro36Pro exon 4 rs1800370 34 2
c.215G>C p.Arg72Pro exon 4 rs1042522 21 12
c.376-91G>A intron 4 rs2909430 0 7
c.639A>G p.Arg213Arg exon 6 rs1800372 33 3
c.672+62A>G intron 6 rs1625895 1 9
c.673-36G>C intron 6 rs17880604 35 1
c.782+72C>T intron 7 rs12947788 30 6
c.782+92T>G intron 7 rs12951053 30 6
c.993+12T>C intron 9 rs1800899 35 1
c.1100+30A>T intron 10 rs17880847 35 1
1Genotypes were not available (not included) for the index case screened in the he
(A) (http://hapmap.ncbi.nlm.nih.gov/) or Exome Variant Server - European American
for rs12947788.(Table 1). Family F1580 (Figure 3) is striking for the num-
ber of reported cases of males with cancer. Gender bias in
TP53 mutation carriers has been reported in independent
studies, where penetrance appears to be higher in females
than males perhaps due to the high penetrance for female
breast cancer [20,21]. However, the mutation carrier status
of all the individuals in carrier families and the familial ori-
gin of the TP53 mutation are unknown.
In all there were seven different TP53 mutations asso-
ciated with French Canadian (Quebec) cancer families at
the initiation of the present study.
No new French Canadian mutation identified in screen of
HBC/HBOC families
A mutation analysis of index cases from 37 HBC/HBOC
families identified 14 sequence variants (Table 2). Eleven
of these variants occurred within intronic sequences and
two resulted in synonymous amino acid substitutions
that are all classified as polymorphisms based on informa-
tion from the IARC TP53, dbSNP and EVS Databases. The
c.215G>C [p.Arg72Pro] polymorphism was found in het-
erozygous/homozygous state in 41.7% (n = 15) of cases.
This polymorphism has been found to be of functional sig-
nificance as the proline amino acid is less efficient than
arginine at codon 72 at inducing apoptosis and this has
been attributed to weaker binding and ubiquitination by
MDM2 of the proline containing isoform [22,23]. Although


















frequencies2BB A A% B B% A% B%
0 71 98.6 1 1.4 94.6 5.5 A
21 18 25.0 54 75.0 26.0 74.0 B
1 59 81.9 13 18.1 79.5 20.5 B
0 71 98.6 1 1.4 94.8 5.2 B
0 70 97.2 2 2.8 98.5 1.5 B
3 54 75.0 18 25.0 78.3 21.7 A
17 7 14.6 41 85.4 9.9 90.1 A
0 69 95.8 3 4.2 98.1 1.9 B
26 11 15.3 61 84.7 10.3 89.7 A
0 71 98.6 1 1.4 98.4 1.6 B
0 66 91.7 6 8.3 - - -
0 66 91.7 6 8.3 92.4 7.6 A
0 71 98.6 1 1.4 98.5 1.5 B
0 71 98.6 1 1.4 98.5 1.5 B
reditary cancer clinic; 2Population based allele frequencies from Hap Map CEU
s (B) (http://evs.gs.washington.edu/EVS/); Population frequency was not known
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parable to a previous analysis of 52 probands from HBC/
HBOC families analyzed for TP53 mutations from our
group [10] and to those reported for European (Caucasian)
populations as reported in the dbSNP and/or EVS Data-
bases (Table 2). Thus no new deleterious mutations
were identified in cancer cases representative of 37
French Canadian HBC/HBOC families found negative
for deleterious BRCA1/ BRCA2 mutations.Targeted mutation screen identifies TP53 mutation-positive
breast cancer cases
Three mutation carriers among the 1235 women with
breast cancer not selected for family history of cancer
were identified in a targeted TP53 mutation screen for
regions containing mutations found in French Canadians
(Table 1). All carriers were among the 656 women who
were diagnosed under 50 years of age. Family histories
of cancer were obtained at interview and this informa-
tion is shown in Figure 6.
The c.844C>T [p.Arg282Trp] mutation is predicted to
affect the DNA binding domain of p53 based on the IARC
TP53 database (Table 1). The carrier of this mutation had
breast cancer at ages 30 and 38, and reported an unremark-
able family history of cancer: a paternal uncle with stomach
cancer in his 40’s and a maternal grandmother with liver
cancer at age 80 (Figure 6). Interestingly, the same mutation
was found in one of six pedigrees (F1583) provided by the
hereditary cancer clinics (Figure 5). Although it is not
known if the carriers are related, their personal and family
histories of cancer are not recognizable in a comparison of
their pedigrees.
The same c.685T>C [p.Cys229Arg] mutation was
found in two women with breast cancer not selected for
cancer family history (Table 1). This mutation is pre-
dicted to affect the DNA binding domain of p53 based
on the IARC TP53 database. The familial relationship of
these carriers is unknown and their reported family his-
tories of cancer are shown in pedigrees F1602 and F1603
(Figure 6). The carrier from family F1602 had breast
cancer at ages 35 and 38, which included a ductal car-
cinoma in situ. This carrier reported a father with pros-
tate cancer estimated to have occurred at ages 57–58,
two paternal aunts with breast cancer between 40–55
years of age, and a paternal uncle with esophageal cancer
at age 57 (Figure 6). The carrier from family F1603 was
diagnosed with breast cancer at age 46. This carrier re-
ported both a paternal and a maternal aunt with breast
cancer between 60–70 years of age, a paternal uncle with
an unspecified cancer at age 80, and a maternal uncle
with brain cancer at age 40. Thus both of these inde-
pendently ascertained mutation carriers had a family
history of breast cancer.Discussion
Although the carrier frequency of TP53 mutations in the
French Canadian population of Quebec is currently un-
known, a picture is emerging of the contribution of this
gene to hereditary breast cancer. In previous studies we
reported that 3.8% (2/52) of HBC/HBOC families nega-
tive for BRCA1 and BRCA2 mutations harbored TP53
mutations [10]. None of the 37 families evaluated in the
present study were found to carry variants predicted to
have deleterious effect on p53 function. As the ascertain-
ment criteria of HBC and HBOC families is the same
across all of our studies in this population, our revised
estimate of the carrier frequency in HBC/HBOC with at
least three cases of breast cancer under 66 years or age
and/or ovarian cancer found negative for BRCA1 and
BRCA2 is approximately 2.2% (2 of 89). Although our
ascertainment criteria differ from independent reports,
this frequency is consistent with the low carrier fre-
quency in HBC/HBOC families found negative for germ-
line BRCA1 and BRCA2 mutations [1].
The TP53 mutations c.685T>C [p.Cys229Arg] and
c.844C>T [p.Arg282Trp] identified in a screen of women
with breast cancer not selected for family history of cancer
are both predicted to effect the DNA binding domain of
p53. The clinical significance c.685T>C [p.Cys229Arg] mu-
tation is unknown as various bioinformatic tools render
neutral to partial functionality of the encoded protein as re-
ported in the IARC TP53 mutation database. However, this
mutation has been reported to occur in somatic cells in the
IARC TP53 mutation database and was also reported as a
germline mutation in a LFS family [24]. In contrast,
c.844C>T [p.Arg282Trp] is predicted to have a deleterious
effect on protein function and has been reported as a com-
mon somatic and germline mutation in the IARC TP53
mutation database. Interestingly, this mutation was found
in family F1583, a carrier family provided to the study by
hereditary cancer clinics (see Table 1, Figure 5). The rela-
tionship between the carriers of the same mutation is un-
known. The mutation carrier in F1583 had a liposarcoma
at age 21 and her mother had breast cancer in her 30’s and
pancreatic carcinoma at age 36 (Figure 5). However, the
mutation carrier status of her mother or other cancer-
affected individuals in the family is unknown. It is tempting
to speculate that when taken together the mutations identi-
fied in breast cancer cases not selected for family history of
cancer are likely pathogenic.
Our findings suggest that less than 0.5% of French
Canadian (Quebec) women with breast cancer carry a
germline TP53 mutation. Our study was limited to an
evaluation of exons five to nine. However a mutation screen
of these exons covers the regions that encode the DNA
binding domain of p53, which we estimate accounts for
74% of germline TP53 mutations according to IARC TP53
Mutation Database. We have not included in our estimate,
Figure 6 Pedigrees from breast cancer case reports of families F1602 and F1603 harboring the TP53 mutation c.685T>C [p.Cys229Arg] and family
F1604 harboring the TP53 mutation c.844C>T [p.Arg282Trp. Cancer type or site followed by age of diagnosis for breast cancer (Br), brain tumor
(Bt), cancer site unknown (CSU), ductal carcinoma in situ (DCIS), esophageal cancer (Eso), liver cancer (Liv), prostate cancer (Pro), and stomach
cancer (Sto). Age in years or age at death (d.) if known at time of ascertainment are shown.
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be of biological significance [22,23]. However, its role as a
modifier of cancer risk is controversial, as large case control
studies by the Breast Cancer Association Consortium found
no significant association with breast cancer risk [25] or
breast cancer risk in BRCA1/BRCA2 mutation carriers
[26]. Our carrier frequency is in keeping with independentmutation screens of breast cancer cases not selected for
family history of cancer or ethnicity [1]. The observation
that all mutation carriers were among the women diag-
nosed under age 50 years is also in keeping with independ-
ent reports and is a reflection of the high penetrance of
mutated TP53 alleles, which is estimated to confer an 18–
60 fold increased risk of breast cancer [1-3].
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with breast cancer under 50 years of age, at 0.5%, is
lower than that estimated for BRCA1/BRCA2 carriers in
the same population. A study of 564 French Canadian
women with breast cancer under 50 years of age re-
ported a 4.8% carrier frequency in a mutation screen for
eight BRCA1/BRCA2 mutations found to recur in
French Canadian HBC/HBOC cancer families [14].
Within this cohort 0.7% and 1.1% were found to harbor
either the PALB2:p.Gln775Ter or CHEK2:c.1100delC
recurrent French Canadian mutations, respectively [14].
A more recent study from the same group, found that
5.3% of French Canadian women with invasive breast
cancer had one of six recurrent BRCA1/BRCA2 muta-
tions [17]. The mutation frequency may be higher, given
that the screen did not include an analysis for
BRCA2:p.Glu3002Lys, a mutation that has been recently
reclassified as pathogenic and found to recur at a low
frequency in French Canadians [27,28]. Thus relative to
BRCA1/BRCA2, germline TP53 mutations are infre-
quent in French Canadian women with breast cancer, and
may be similar (if not lower than) the mutation frequencies
observed for specific PALB2 and CHEK2 mutations ob-
served for this population.
The identification of carriers with the same c.685T>C
[p.Cys229Arg] or c.844C>T [p.Arg282Trp] mutation in
TP53 is not surprising given the founder effects ob-
served in the French Canadian population [29]. Reports
of recurrent TP53 mutations due to common founders
have been rare [5]. For example, the recurrence of
p.Arg337His variant appears to be the cause of the high
incidence of childhood ACC in Southeastern Brazil
[30,31]. However, the familial relationship of the carriers
of identical TP53 mutations in our study is not known.
The low frequency of carriers and broad spectrum of
mutations identified does not warrant a targeted screen
for these mutations at the present time, as has been rec-
ommended for recurrent mutations in BRCA1 and
BRCA2 [12,14,17]. Also, it is possible that the carriers
are closely related as was discovered in our previous
study of independently ascertained families F1444 and
F1039 [10] and in a case review of families F1581 and
F187 in the present study.
Our results raise the question of routine TP53 mutation
testing in women with breast cancer. None of the carrier
women with breast cancer from the cohort not selected
for family history of cancer, reported a family history of
cancer that would have warranted an investigation of
TP53 in clinical settings as has been recommended for
LFS (Figure 6). The identification of TP53 mutation car-
riers would identify those women who are predicted to
have an abnormal response to low dose radiation [4].
Moreover, it may identify family members at risk for
breast cancer and other malignancies associated with LFS[5]. Counseling issues are complex with TP53 mutation
carriers due to the spectrum of cancer type involved, par-
ticularly where there are few options for cancer surveil-
lance or prevention [2]. In Canada, all genetic testing for
TP53 (and BRCA1 and BRCA2) can only be ordered by
cancer genetics professionals associated with a medical
genetics clinic, which are managed by provincial health
care jurisdictions. Currently there are no official testing
guidelines in the province of Quebec and no routine test-
ing of women with breast cancer. Women are referred to
genetic counseling units for further assessment prior to
genetic testing. It may be difficult to advocate genetic
testing of breast cancers regardless of family history of
disease in the province of Quebec, especially given the
low frequency of mutation carriers. However, the risk
for female breast cancer risk is high in mutation car-
riers and nonionizing cancer surveillance methods are
available for carriers [2]. Recently recommendations by
the National Comprehensive Cancer Network® have
been made to revise practice guidelines, which recom-
mend TP53 mutation testing for women with breast
cancer diagnoses under of the age of 35 years [9]. How-
ever these guidelines when applied to women with
breast cancer in our study would have identified only
three of the seven mutation carriers (see Table 1). As
mutation analysis becomes more cost effective through
the use of multiplexed mutation screens or whole ex-
ome sequencing, our findings would support the
screening of TP53 as part of the panel of breast cancer
susceptibility genes investigated in high risk women
and women with breast cancer.
Conclusions
New germline TP53 mutations were identified in French
Canadians with cancer, a population that exhibits a unique
genetic demography due to common founders. Mutation
carriers included women diagnosed with breast cancer be-
fore 50 years of age. None of these women had a family his-
tory of cancer consistent with LFS. Our findings further
define the spectrum and frequency of germline TP53 muta-
tions in women with breast cancer not selected for family
history of cancer and could further inform the development
of mutation screening policies for French Canadians in
Quebec.
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